A detailed history of Algert Global LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Algert Global LLC holds 51,660 shares of IMVT stock, worth $1.42 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
51,660
Previous 49,661 4.03%
Holding current value
$1.42 Million
Previous $2.09 Million 20.22%
% of portfolio
0.07%
Previous 0.08%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$30.27 - $43.79 $60,509 - $87,536
1,999 Added 4.03%
51,660 $1.67 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $432,328 - $610,175
-13,808 Reduced 21.76%
49,661 $2.09 Million
Q3 2023

Nov 13, 2023

SELL
$18.55 - $39.96 $300,324 - $646,952
-16,190 Reduced 20.32%
63,469 $2.44 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $574,674 - $961,162
40,470 Added 103.27%
79,659 $1.51 Million
Q1 2023

May 12, 2023

BUY
$15.27 - $19.72 $598,416 - $772,807
39,189 New
39,189 $608,000
Q3 2022

Nov 15, 2022

SELL
$3.93 - $6.37 $170,793 - $276,833
-43,459 Reduced 34.44%
82,741 $462,000
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $34,229 - $57,217
-10,127 Reduced 7.43%
126,200 $492,000
Q1 2022

May 16, 2022

BUY
$5.06 - $8.77 $689,814 - $1.2 Million
136,327 New
136,327 $751,000
Q3 2021

Nov 15, 2021

SELL
$7.01 - $11.37 $201,257 - $326,432
-28,710 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$9.4 - $16.85 $360,988 - $647,090
-38,403 Reduced 57.22%
28,710 $303,000
Q1 2021

May 14, 2021

BUY
$13.08 - $49.6 $877,838 - $3.33 Million
67,113 New
67,113 $1.08 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.